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We have previously shown that repeated sequential administration of doxorubicin, followed 24 h later
by zoledronic acid, inhibits tumour growth in models of established breast cancer bone metastasis. As
breast cancer patients only receive zoledronic acid every 3–4 weeks, the aim of the current study was to
establish the anti-tumour and bone effects of a single administration of doxorubicin/zoledronic acid
combination therapy in a bone metastasis model.
MDA-MB-231-GFP cells were injected i.c. in 6-week-old nude mice. On day 2, animals received PBS,
doxorubicin (2 mg/kg i.v.), zoledronic acid (100 mg/kg s.c.) or doxorubicin followed 24 h later by
zoledronic acid. Anti-tumour effects were assessed on days 15/23 by quantiﬁcation of apoptotic and
proliferating cells and changes in expression of genes implicated in apoptosis, proliferation and bone
turnover. Bone effects were assessed by mCT analysis, bone histomorphometry and measurement of
serum markers. A tumour-free control group was included.
Combination treatment reduced bone tumour burden compared to single agent or PBS control and
increased levels of tumour cell apoptosis on day 15, but this was no longer detectable on day 23. Animals
receiving zoledronic acid had increased bone density, without evidence of tumour-induced lesions. Bone
histomorphometry showed that zoledronic acid caused a decrease in osteoblast and osteoclast numbers
and an increase in osteoclast size, in both tumour-free and tumour-bearing animals.
Our data show that although zoledronic acid modiﬁes the bone microenvironment through effects on
both osteoblasts and osteoclasts, this does not result in a signiﬁcant anti-tumour effect in the absence of
doxorubicin.
& 2012 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patients with breast cancer bone metastasis may be treated
with a combination of chemotherapy, often an anthracyclin, in
addition to the potent anti-resorptive bisphosphonate (BP) zole-
dronic acid. The optimisation of combination therapy in this
setting has been the subject of a number of in vitro and in vivo
studies. The majority of these have shown beneﬁcial effects of
BPs, alone or in addition to standard therapy, of a variety of
tumours in and outside bone (reviewed in [1,2]). A comprehen-
sive comparison of the bone studies suggests that improved. This is an open access article un
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.K. Brown).outcome may require earlier initiation of BP treatment schedule
than that currently recommended for patients with metastatic
bone disease [1]. We have found that even small tumour colonies
induce major changes to the microenvironment before overt
osteolysis is detected [3]. Early intervention may therefore be
necessary to inhibit homing and growth of the tumour cells at the
metastatic site.
The clinical relevance of bisphosphonates as anti-cancer
agents has been subject to considerable debate and results
relating to anti-tumour effects from clinical trials of bispho-
sphonates have been conﬂicting, with some reporting direct
anti-tumour effects [4,5] and some not [6]. However, the recently
reported AZURE trial demonstrated that adjuvant zoledronic acid
combined with chemotherapy in high-risk breast cancer patients
did not result in increased overall survival in all patients [7].
Surprisingly, post-menopausal women did beneﬁt from adjuvant
zoledronic acid, with approximately 30% increase in overall
survival compared to those receiving chemotherapy alone, sug-
gesting that the endocrine environment plays a key role in
determining the response to therapy. The cellular and molecularder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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established, and there is clearly a need for more detailed inves-
tigations of effects of therapy on the bone microenvironment.
In order to treat metastatic bone disease effectively all steps
involved in the metastatic cascade need to be taken into account
as for example the interactions between primary and secondary
sites, tumour cell–bone cell cross talk and osteomimicri [8].
Therefore, concomitant targeting of both the tumour and the
bone microenvironment is likely to be required. Bisphosphonates
have been combined with chemotherapy agents in models of
bone metastasis from both breast and prostate cancer (reviewed
in [2,9]). An intensive dosing regimens of docetaxel and risedro-
nate (4 mg/kg docetaxel twice a week, 150 mg/kg risedronate
5 times a week), has been shown to eliminate osteolytic bone
disease and cause a substantial inhibition of tumour growth in a
MDA-231luc model, compared to the single agents [10]. Similarly,
Brubaker et al. found that repeated administration of zoledronic
acid and docetaxel (100 mg/kg zoledronic acid twice a week and
20 mg/kg docetaxel every 2 weeks) was superior to the single
agents at inhibiting growth of established LuCaP 23.1 prostate
cancer bone metastases [11].
Using clinically achievable dosing regimens we have pre-
viously demonstrated a substantial, sequence-dependent, anti-
tumour activity of doxorubicin (2 mg/kg) and zoledronic acid
(100 mg/kg) in vivo. Six cycles of weekly administration of the two
agents induced signiﬁcant and sustained reduction in the growth
of s.c. MDA-MB-436 xenografts [12,13], osseous breast tumours
[14] and inhibition of development of spontaneous mouse mam-
mary tumours [15]. The clinical relevance of these studies is
unclear, as patients currently receive zoledronic acid only once
every 3–4 weeks, compared to the 6 weekly doses, and agents are
routinely given on the same day rather than after a 24-hour gap.
In a model of advanced bone metastasis with established lytic
lesions, we have shown that a single administration of zoledronic
acid given 24 h after the ﬁrst cycle of weekly doxorubicin does
reduce intra-osseous tumour growth [16]. However, starting
treatment at this late stage of the disease did not have major
impact on progression or survival, suggesting that earlier inter-
ventions are required to achieve signiﬁcantly improved outcomes.
In the present study we have therefore investigated whether
administration of a single round of clinically achievable combina-
tion therapy at an early stage of bone metastasis development can
prevent tumour progression in bone. Due to the increasing
importance of the microenvironment in osseous tumour growth
[17], we have also performed a detailed analysis of the effects of
the therapeutic agents on bone cells, both in the presence and
absence of tumour. Our data show that a single dose of zoledronic
acid modiﬁes both osteoblasts and osteoclasts, regardless of the•PBS
•Doxorubicin (2mg/kg, i.v.)
•Zoledronic acid (100 µ g/kg, s.c.)
•Dox followed 24 hrs later by zol
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Fig. 1. Study protocol assessing treatment-effects on tumour-free and tumour-bearing b
MDA-MB-231-GFP cells on day 0. All animals (including tumour-free mice) were treate
doxorubicin followed 24 h later with zoledronic acid, animals were sacriﬁced on day 1presence of tumours. Despite zoledronic acid causing sustained
increase in trabecular bone volume, there was no reduction in
bone tumour burden without the addition of doxorubicin. Early
administration of combination therapy caused a substantial but
transient suppression of tumour growth, indicating that repeated
courses of treatment are required for optimal anti-tumour effects.2. Materials and methods
2.1. Maintenance of cell line and tumour growth model
Human MDA-MB-231 breast cancer cells stably expressing green
ﬂuorescent protein (GFP) were maintained in RPMI-1640 (GIBCO)
supplemented with 10% foetal calf serum and 1% penicillin/strepto-
mycin (PAA Laboratories) and grown at 37 1C and 5% CO2.
All experiments were carried out in accordance with local
guidelines and with Home Ofﬁce approval under project licence
40/2972 held by Professor N.J. Brown, University of Shefﬁeld,
United Kingdom. MDA-MB-231-GFP cells (1105) were injected
into the left heart ventricle of 6 week old female balb/c nu/nu
mice under general anaesthesia induced by 100 mg/kg ketamine
(Fort Dodge Animal Health Ltd) and 15 mg/kg xylazine (Bayer
plc). A total of n¼15 (sacriﬁced on day 15) and n¼10 (sacriﬁced
on day 23) tumour-bearing mice/group were used in addition
to 24 tumour-free animals (n¼3/group, sacriﬁced on day 15).
All animals were randomised into 4 treatment groups: (1) PBS,
(2) doxorubicin (2 mg/kg i.v.), (3) zoledronic acid (100 mg/kg s.c.)
and (4) doxorubicin followed 24 h later with zoledronic acid.
Treatment was initiated 2 days post tumour cell injection (Fig. 1).
At the end of the protocol, food was removed and some animals
were injected intraperitoneally with 400 mg/kg bromodeoxyur-
idine (BrdU; Sigma-Aldrich, 3 h before sacriﬁce) before blood was
collected under deep non-recovery anaesthesia. For mice sacri-
ﬁced on day 15, hind legs were ﬁxed in PFA, scanned by mCT prior
to decalciﬁcation. On day 23, right hind legs were processed as
above while bone marrow and tumours of the left hind legs were
used for gene expression analysis.
2.2. Measurement of tumour area
Histological sections (3 mm) of decalciﬁed hind legs were stained
with H&E and analysis was carried out using Osteomeasure soft-
ware. Tumour area (mm2) was measured on 2–3 non-serial sections
per sample by interactively measuring all visible tumour foci. Intra-
and extraosseous tumour areas were scored separately. Sections
stained using Goldner’s trichrome staining kit (Merck) was per-
formed for exemplatory visualisation purposes only.Sacrifice and
sample collection
Day 15
Day 15
Day 23
Sacrifice and
sample collection
ones. For the tumour study, balb/c nude mice (female, 6 weeks) were injected with
d on day 2 with PBS, doxorubicin (2 mg/kg i.v.), zoledronic acid (100 mg/kg s.c.) or
5 or 23.
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For immunohistochemical analysis of tumour cell apoptosis
and proliferation, two non-serial sections per tumour sample
were stained for BrdU (day 15), Ki67 (day 23) and caspase-3
(day 15 and 23) as previously described in [13,16]. Caspase-3
staining was performed using rabbit polyclonal anti-active cas-
pase-3 (AF835, R&D Systems; 1:750) followed by a biotin-con-
jugated anti-rabbit secondary antibody (BA-1000, Vector
Laboratories; 1:200). Staining for the proliferation marker Ki67
was carried out using an anti-human Ki67 mouse monoclonal
antibody (MIB-1, DakoCytomation; 1:125) followed by a biotin-
conjugated anti-mouse secondary antibody (BA-2000, Vector
Laboratories, 1:200). Immunohistochemistry for BrdU was done
using mouse anti-human BrdU (Clone Bu20a, M0744, DakoCyto-
mation; 1:175) and a biotin conjugated anti-mouse secondary
antibody (BA-2000, Vector Laboratories; 1:200). The number of
DAB positive cells per mm2 tumour area was scored using a Leica
BMRB upright microscope and Osteomeasure software with a 10x
objective. Intra- and extra-osseous tumour area were scored
separately.
2.4. Tartate-resistant acid phosphatase (TRAP) staining
and bone cell scoring
TRAP staining was used for all osteoclast (Oc) quantiﬁcations.
Brieﬂy, dewaxed sections were incubated in acetate–tartrate
buffer at 37 1C for 5 min followed by incubation in naphthol
AS–BI phosphate, dimethylformamide in acetate–tartrate buffer
for 30 min at 37 1C. Finally sections were placed in a solution
containing sodium nitrite, pararosaniline and acetate–tartrate
buffer for 15 min at 37 1C, before counterstaining in haematox-
ylin. The number of TRAP stained osteoclasts per millimetre
trabecular bone surface was scored using a Leica RMRB upright
microscope with a 10x objective and OsteoMeasure software
(Osteometrics). In the same sections, osteoblasts were scored
per millimetre trabecular bone surface in line with previously
published studies [18–21]. At least two non-serial sections were
analysed per sample and all trabecular bone surfaces were scored.
For measurements of osteoclast size, the area of TRAP stained
osteoclasts was analysed using OsteoMeasure software. Data are
expressed as mean osteoclast size in mm2.
2.5. Microcomputed tomography imaging
Microcomputed tomography analysis was carried out using a
Skyscan 1172 X-ray-computed microtomograph (Skyscan). Ima-
ging was carried out at a voltage of 50 kV and a currency of
200 mA with a medium camera resolution of 20001024, an
aluminium ﬁlter of 0.5 mm and pixel size was set to a dimension
of 4.3 mm. Scanning was initiated from the proximal tibia or distal
femur. For each sample, images were reconstructed with NRecon
software. The volume of interest (VOI) was then speciﬁed by
interactively drawing on the two-dimensional acquisition images.
For trabecular bone measurements, the VOI was composed only of
cancellous bone, and the cortices were excluded. Trabecular bone
volume (BV/TV in %, which is deﬁned as the percentage of the
volume of interest occupied by binarised solid objects) was
calculated covering 1 mm, starting from the lowest part of the
growth plate.
2.6. Statistical analysis
Prism GraphPad (Version 5.0a) was used for all statistical
analysis. Analysis was by t-test or one-way ANOVA followed by
Tuckey post-test. The applied test is indicated in each ﬁgurelegend. All data are shown as mean7SEM and differences have
been interpreted as being signiﬁcant at pr0.05.3. Results
This study used an established model of bone metastasis
where intracardiac injection of MDA-MB-231 breast cancer cells
result in tumour growth in the long bones of nude mice. As shown
in Fig. 1, treatment was administered on days 2–3 following
tumour cell injection, to allow tumour cell homing and initial
colonisation of skeletal sites. Animals were sacriﬁced either on
day 15 or day 23. A parallel experiment was performed using
animals without tumours, terminated on day 15, to allow assess-
ment of treatment-induced effects in a tumour-free bone
microenvironment.
3.1. A single dose of combination therapy inhibits tumour growth
in bone
Previous in vivo studies have shown that repeated adminis-
tration of doxorubicin followed 24 h later by zoledronic acid
induced a signiﬁcant reduction of breast tumour growth at
various sites, including bone. As shown in Fig. 2A, a single, early
dose of combination treatment was sufﬁcient to effectively
reduce bone associated tumour growth on day 15 compared to
mice treated with PBS or zol alone (PBS 0.16 mm2 vs. dox then zol
0.03 mm2, po0.05) and this was maintained on day 23 (PBS
0.97 mm2 vs. dox then zol 0.17 mm2, po0.001). The combination
treatment was the only therapeutic strategy used in this study
that induced a sustained anti-tumour effect. Doxorubicin alone
inhibited total tumour growth only transiently (day 15, PBS
0.16 mm2 vs. dox 0.04 mm2, po0.05), but was not sufﬁcient to
affect later stages of tumour progression (day 23, PBS 0.95 mm2
vs. dox 0.92 mm2, p40.05). Differential analysis of intra- vs.
extra-osseous tumour area showed that the combination treat-
ment had a major effect on intraosseous tumour growth, with
only 1 animal out of 6 having detectable tumour foci in the bone
marrow cavity on day 23 (Fig. 2C). In addition, extraosseous
tumour growth in the combination group at day 15 was reduced
by 29% (po0.05) compared to that in animals receiving PBS (data
not shown).
To determine whether the observed reduction in tumour size
was due to treatment-induced changes in apoptosis and/or
proliferation, caspase-3, Ki67 and BrdU immunohistochemistry
were performed. Quantiﬁcation of active caspase-3 positive
tumour cells on day 15 showed that only the combination
treatment caused a signiﬁcant increase in the number of apopto-
tic tumour cells (dox then zol 166.62 vs. PBS 83.64, po0.01,
Fig. 3A). This effect was lost over time as no difference between
any of the groups was detected on day 23 (Fig. 3B). Differential
analysis of intra- and extraosseous tumour areas showed that the
increase in overall tumour cell death in the combination group
was due to an increase in apoptosis in tumours growing outside
the bone marrow cavity on day 15. The data are in agreement
with the observed decrease in extraosseous tumour area on this
day. In addition, doxorubicin mono-therapy increased the number
of apoptotic tumour cells in the intra but not the extraosseous
tumour foci, again mirroring the effects on tumour size on day 15
(Fig. 2). No change in the number of caspase-3 positive tumour
cells was observed in any treatment group on day 23 indicating
that the effect on tumour cell apoptosis was only transient. This
was supported by a lack of change in apoptotic genes (BCL2,
CRADD) in tumours isolated from this treatment group (data not
shown). Tumour cell proliferation was not signiﬁcantly reduced
by any of the treatment schedules, with tumours at day 15 and 23
Day 23 Intra-osseous 
tumour
Extra-osseous 
tumour
PBS 7/7 7/7
Doxorubicin 5/5 2/5
Zoledronic acid 5/5 5/5
Doxorubicin 
followed by 
zoledronic acid
1/6 5/6
Intraosseous 
tumour
Extraosseous
tumour
B
BM
GP
Fig. 2. Effects of combination therapy on tumour burden. (A) Analysis of total tumour area (mm2) performed on a minimum of 2 non-serial sections per sample using a 4x
objective. One way ANOVA and Tuckey post test, * is po0.05, ** is po0.01, *** is po0.001, ns¼not signiﬁcant. (B) Example Goldner’s trichrome stained section depicting
extra- and intra-osseous tumour foci. (C) Number of mice on day 23 with intra- and extra-osseous tumour colony detected by histology.
H.K. Brown et al. / Journal of Bone Oncology 1 (2012) 47–5650showing high levels of Ki67/BrdU positive cells, regardless of
whether they were located inside or outside the bone marrow
cavity (Fig. 3C and D).
These results show that a single dose of combination therapy
is sufﬁcient to reduce tumour growth inside the bone marrow
cavity, most likely due to increased levels of tumour cell apoptosis
in the ﬁrst few days after administration.3.2. Effects of therapy on naı¨ve v.s. tumour bearing bone
We next investigated the treatment-induced effects on bone
structure, comparing bones from tumour-free and tumour-bear-
ing animals. Analysis was performed in the regions of bone most
commonly colonized by tumours in this model (proximal tibia/
distal femur). This allowed us to identify the bone-speciﬁc effects
Fig. 3. Effects on caspase-3 and Ki67/BrdU. Histological sections were stained for caspase-3 to detect apoptotic tumour cells. Data are expressed as number of positive cells
per tumour area in mm2 for (A) day 15 and (B) day 23. Staining for (C) BrdU (day 15) or (D) Ki67 (day 23) was performed to detect tumour cell proliferation At least 2 non-
serial sections per sample were analysed using a 10x objective. One way ANOVA and Tuckey post test, ** is po0.01 vs. PBS control, ns¼not signiﬁcant.
Fig. 4. Effects on bone structure and integrity in the absence of tumour.
Quantiﬁcation of trabecular bone volume per tissue volume (BV/TV) for tumour-
free animals sacriﬁced on day 15. One way ANOVA and Tuckey’s post test, *** is
po0.001 compared to control and þþþ is po0.001 compared to doxorubicin.
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induced bone disease. As shown in Fig. 4, a single administration
of zoledronic acid, alone or in combination with doxorubicin, had
profound effects on bone structure assessed by mCT. BV/TV was
signiﬁcantly increased compared to control (PBS 7.51% vs. zol
21.33% and dox followed by zol 22.60%, both po0.001), mainly
due to increased trabecular number. Doxorubicin did not affect
trabecular bone structure compared to saline control, hence there
was no chemotherapy-induced bone loss following the dose/
schedule used in this study.In tumour bearing animals, tumour growth was detected in hind
legs of animals from all treatment groups, suggesting that none of the
agents completely prevented the initial steps of tumour cell homing,
colonisation and growth. Foci were generally located around the knee
joint in the proximal tibia and/or distal femur (for examples see
Fig. 5C and D), but were not associated with extensive bone
destruction at termination on day 23. mCT analysis showed that a
single dose of zoledronic acid administered two days post tumour cell
injection signiﬁcantly increased trabecular bone volume when com-
pared to PBS or single agents (zol 29.24% and dox then zol 22.43% vs.
PBS 8.4%, both po0.001 on day 15; zol 28.09% and dox then zol
32.39% vs. PBS 6.1%, both po0.001 on day 23, Fig. 5A and B). As was
seen in tumour-free animals, doxorubicin did not reduce trabecular
bone volume when compared to control at any time point. Further
analysis revealed that the positive effects of treatment on bone
volume were mainly due to an increase in trabecular number, rather
than thickness. Examples of bone cross sections from each treatment
group and time point are depicted in Fig. 5C and D.3.3. Treatment-induced changes of the bone
microenvironment—effects on osteoblasts and osteoclasts
Therapeutic schedules that include zoledronic acid are likely to
cause alterations in the bone microenvironment, but it is unclear
how combination treatment affects the different cellular com-
partments in the region of the bone–tumour interphase. We
therefore compared the effects of both single agents and combi-
nation therapy on osteoblast (Ob) and osteoclast (Oc) numbers in
a tumour-free and a tumour-bearing setting.
Fig. 5. Effects on bone structure and integrity in tumour-bearing bones. Analysis of osteolytic bone disease was carried out for the proximal tibia and the distal femur in
animals sacriﬁced on (A) day 15 and (B) 23. Data are expressed as trabecular bone volume per tissue volume (% BV/TV). One way ANOVA and Tuckey’s post test, *** is
po0.001 compared to naı¨ve, PBS or dox; ^ is po0.05 vs. naı¨ve and  is po0.05 vs. zol; ns¼not signiﬁcant. Cross sections taken from mCT scans of the proximal tibia and
images of GFP foci in bone are shown in for (C) day 15 and (D) day 23.
H.K. Brown et al. / Journal of Bone Oncology 1 (2012) 47–5652Detailed histomorphometric analysis of bones from tumour-
free animals (day 15) showed a dramatic reduction in Ob number/
mm bone following treatment with zol, either alone or following
dox (PBS 10.21 vs. zol 1.63 and combination 1.74, both po0.001,
Fig. 6A). Similar effects were seen in tumour-bearing bones where
zoledronic acid treatment inhibited the tumour-induced increase
in osteoblast number seen in PBS control (zol 5.43 vs. PBS 13.59,
po0.001) and induced further reductions at day 23 (zol 0.86 vs.
PBS 3.04, po0.05, Fig. 7A). The effects of therapy on Ob numbers
were reﬂected by a decrease in serum levels of the bone forma-
tion marker PINP on day 15 (PBS 42.17 ng/ml vs. zol 22.8 ng/ml,
po0.05). Differences in PINP levels were no longer detectable by23 (data not shown), probably due to the 3-week interval
between treatment and sample collection.
In line with the reported anti-resorptive activity, zoledronic
acid caused a reduction in osteoclast numbers in animals without
tumour on day 15 (zol 4.22 vs. PBS 6.75, po0.05, Fig. 6B).
However, this effect was not seen in animals with tumours in
bone on day 15 (Fig. 7B). This was surprising considering the zol-
induced increase in trabecular bone volume detected by mCT at
this time point (Fig. 5). At the later time point (day 23), osteoclast
numbers in mice treated with zol or the combination treatment
were reduced, with a signiﬁcant change in the zol treated group
compared to PBS control (zol 1.59 vs. 3.04, po0.01, Fig. 7B). In
Fig. 6. Treatment effects on osteoblast and osteoclast numbers in tumour-free bone. Animals were treated with PBS, 2 mg/kg dox, 100 mg/kg zol or combination therapy on
day 2. Osteoblast (A) and osteoclast (B) numbers were analysed per mm trabecular bone surface on a minimum of 2 non-serial TRAP stained sections per sample. One way
ANOVA and Tuckey post test, * is po0.05 and *** is po0.001 compared to PBS control; þ is po0.05 vs. dox; ns¼not signiﬁcant.
H.K. Brown et al. / Journal of Bone Oncology 1 (2012) 47–56 53agreement with the mCT data, doxorubicin did not affect the
numbers of osteoblast or osteoclasts at either time point when
compared to PBS control.
Although alterations in bone cell numbers are expected to
indicate major treatment-induced effects, changes in cell mor-
phology and activity may be equally important. We therefore
performed a comprehensive analysis to establish the effects of the
different treatments on osteoclast size, both in the presence and
absence of tumour. In the tumour-free group, bones from zole-
dronic acid treated animals had signiﬁcantly larger osteoclasts
(measured in mm2) compared to animals in the PBS control group
(PBS 1.1104 mm2 vs. Zol 1.9104 mm2 and vs. combination
1.9104 mm2, both po0.001, Fig. 8A). This effect was also
observed at both time points in the tumour-bearing animals (PBS
1.9104 mm2 vs. Zol 3.3104 mm2 on day 15, po0.001 and
PBS 2.3104 mm2 vs. Zol 3.7104 mm2 on day 23, po0.01,
Fig. 8B). As illustrated in Fig. 8C, the majority of the osteoclasts in
the zoledronic acid treated animals displayed a changed mor-
phology compared to control, appearing bigger, thicker and
covering large areas of bone. However, there were no differences
in the levels of circulating CTX (bone resorption marker) between
any of the treatment groups, probably due to the interval between
treatment and serum sample collection (data not shown). Collec-
tively the data indicate an initial effect of zoledronic acid on
osteoclast activity, rather than by causing a decrease in osteoclast
number.4. Discussion
This is the ﬁrst report to show that a single administration of
doxorubicin followed by zoledronic acid at an early time point
(day 2 following tumour cell injection) is sufﬁcient to cause
signiﬁcant inhibition of breast tumour growth in bone. The
experiments were designed to allow comparison of treatment-
induced effects over time and to establish whether these were
sustained in the 3 weeks following administration of therapy. The
inclusion of both tumour free and tumour-bearing animals is
unique to our study, allowing us to identify and compare treat-
ment-induced effects on bone in the presence and absence of
tumour.
Our data show that, despite zoledronic acid having a substan-
tial effect on bone, tumour growth was only reduced in animalsthat received combination therapy. This is in agreement with a
number of studies reporting a lack of anti-tumour effects after
bisphosphonate monotherapy. The basis of combination therapy
is to effectively reduce tumour growth by targeting both the
tumour and the microenvironment at the metastatic site. In
agreement with previous studies [12–14,16], we found that only
tumours from the combination group exhibited signiﬁcant differ-
ences in apoptosis on day 15, mirroring the reduction in tumour
area. No changes in active tumour cell proliferation were detected
at either time point. In addition, genes regulating apoptosis and
proliferation showed to be signiﬁcantly altered following 6 weekly
cycles of combination therapy [14] were unchanged after the
single cycle given in the present study. This is probably due to
differences in treatment scheduling and sample collection points,
as in the earlier investigations tumours were collected for
analysis 24 h after the ﬁnal administration of repeated cycles of
combination therapy. The data suggest that apoptotic cell death
and reduction in proliferation is likely to be an acute effect of
combination therapy, and therefore no longer detectable 2–3
weeks following administration of treatment. These results
clearly demonstrate that repeated cycles of combination therapy
is required to maintain an anti-tumour in bone effect beyond
1–2 weeks.
The effects of zoledronic acid are most likely due to impair-
ment of the tumour-driven alterations to the bone microenviron-
ment. This may render the bone marrow cavity unfavourable for
metastatic growth, potentially redirecting tumour cells to other
sites, including the periosteal surface. Whereas combination
therapy substantially reduced tumour growth inside the bone
marrow cavity, growth in the periosteum was unaffected. There is
preclinical evidence that bisphosphonate treatment exhibits
stronger anti-tumour effects in the bone marrow cavity compared
to the extraosseous bone-associated soft tissue when given alone
or in combination with cytotoxic agents. Studies investigating the
effects of bisphosphonates as a single agent have reported either
no effect on extraosseous tumour growth after pamidronate or
olpadronate treatment [22] or increased bone-associated soft
tissue tumours after risedronate [23] or the third generation
bisphosphonate YH529 [24]. Collectively the data from these
studies suggest that the bisphosphonate-induced inhibition of
bone remodelling may redirect tumour growth to extraosseous
sites. We have previously shown that doxorubicin given 24 h after
zoledronic acid induced signiﬁcantly increased levels of tumour
Fig. 7. Treatment effects on osteoblast and osteoclast numbers in tumour bearing
bone. Animals were treated with PBS, 2 mg/kg dox, 100 mg/kg zol or combination
therapy on day 2. Osteoblast (A) and osteoclast (B) numbers were analysed per
mm trabecular bone surface on a minimum of 2 non-serial TRAP stained sections
per sample. One way ANOVA and Tuckey post test, * is po0.05, ** is po0.01 and
*** is po0.001 compared to PBS control; þ is vs. dox and ^ is vs. naı¨ve; ns¼not
signiﬁcant.
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large MDA-MB-231/B02 tumours, whereas the extraosseous parts
of the same tumour were unaffected [16]. The present data are in
agreement with these reports, showing that a single dose of
combination treatment effectively reduced tumour growth inside
the bone marrow cavity, but did not eliminate extraosseous
tumour growth. Importantly, the tumour colonies growing along
the periosteal surface were not part of a large, intraosseous
tumour spilling through osteolytic lesions but were separate
tumour colonies. This could suggest that during the process of
tumour cell dissemination, the cells seed to multiple sites but
remain dormant until triggered to proliferate or that cells pre-
viously settled in the bone marrow cavity disseminated to other
sites at relatively early stages of tumour progression (prior to day
15). There are few and opposing published reports relating to the
effects of bisphosphonates on the cells of the periosteum, with the
majority of studies focusing on characterisation of endosteal bonesurfaces [25]. Risedronate and alendronate are reported to inhibit
periosteal osteoblast activity independently of bone resorption
[26]. In contrast, risedronate, alendronate or zoledronic acid were
found to have no signiﬁcant effect on periosteal bone formation in
oestrogen-deﬁcient rats [27]. The role of the periosteal micro-
environment in development and progression of bone metastasis,
as well as in response to therapy, therefore remains to be
established. Our data suggest that development of improved
therapeutic interventions must include control of tumour coloni-
sation of periosteal sites, in addition to growth in the bone
marrow cavity.
Studies of therapeutic agents in xenograft models of bone
metastases are often limited to assessment of tumour burden (by
imaging) and gross bone integrity (by mCT). To fully understand
the effects of therapeutic interventions, we also characterised the
treatment-induced changes of the key cell populations in the host
bone microenvironment. In the absence of tumour, a single dose
of zoledronic acid, given alone or in combination with doxorubi-
cin, caused a signiﬁcant reduction of both osteoclast and osteo-
blast numbers on day 15. Surprisingly, the effect on osteoblasts
was the most pronounced, indicating that zoledronic acid either
caused inhibition of osteoblast development, induction of osteo-
blast apoptosis, or both. Further studies speciﬁcally designed to
distinguish between these options are needed. Evidence that
bisphosphonates can be internalised by osteoblasts in vivo is
reported by Idris et al. [28] who detected unprenylated Rap1a in
bone forming cells derived from mouse calvaria 24 h after
administration of 0.1 mg/kg alendronate. In agreement with this,
Orriss et al. [29] demonstrated that zoledronic acid affects
osteoblast development and function in vitro. Although the
literature is frequently questioning the in vivo effect of bispho-
sphonates on cells other than osteoclasts [30,31], the data shown
in the present study support that a single, clinically achievable
dose of zoledronic acid clearly affects osteoblasts. However, we
were unable to determine whether the observed effects were due
to zoledronic acid affecting osteoblasts directly, or whether the
effects were downstream of the osteoclast effects. Well-recog-
nised feedback loops exist between these cell types as a part of
normal bone homoeostasis. As the anti-resorptive effect of zole-
dronic acid is evident soon after administration of a single dose
[32] it is most likely that the effects on actively resorbing
osteoclasts precede the osteoblast effects.
mCT analysis of tumour bearing bones showed signiﬁcantly
increased bone density in animals receiving zoledronic acid, alone
or in combination with doxorubicin, compared to PBS control. Our
results conﬁrmed that a single dose of zoledronic acid caused
sustained bone effects throughout the experiment (until day 23).
Despite this, the effects on bone cell numbers in the tumour-
bearing environment were less prominent than those detected in
the tumour-free bones, possibly due to the strong inﬂuence the
tumour cells have on bone turnover at the metastatic site. No
reduction in osteoclast number was detected on day 15 although
mCT analysis clearly showed a dramatic increase in bone volume.
In agreement with our previous study using a 6-week regimen in
established, intratibial MDA-MB-436 tumours [14], zoledronic
acid, as well as combination therapy, caused a decrease in
osteoclast numbers compared to PBS control on day 23. Zole-
dronic acid could not only cause a reduction in the number of
osteoclasts, but more importantly reduce their activity. We
suggest that the morphological changes observed in osteoclasts
from the zoledronic acid treated animals reﬂect this, as was
shown by scoring of mean osteoclast area. The presence of ‘‘giant’’
osteoclasts has also been reported after long-term alendronate
treatment in an osteoporotic setting [33]. The authors proposed
that aminobisphosphonates effectively inhibited osteoclast activ-
ity and prolonged the lifespan of the cells, ultimately leading to an
Fig. 8. Effects on osteoclast size. Measurement of osteoclast size (expressed as mean area in mm2) for osteoclasts in (A) tumour-free mice and (B) tumour-bearing animals.
Data are shown as mean7SEM, One way ANOVA and Tuckey post test, * is po0.05, ** is po0.01, *** is po0.001, ns¼not signiﬁcant. Black columns: grey columns: day 23.
(C) Example images of TRAP stained osteoclasts (red) for each treatment group on day 15, scale bar ¼50mm. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
H.K. Brown et al. / Journal of Bone Oncology 1 (2012) 47–56 55increase in cell size due to continuous fusion of the osteoclast
with mononuclear precursors. In addition, apoptosis was detected
in about 30% of the ‘‘giant’’ cells [34]. The data therefore suggest
that bisphosphonate therapy decreases osteoclast activity and
induces changes cell morphology before reducing viability. Pro-
longed/repeated treatment may not be required to generate this
effect, as we have consistently noted larger osteoclasts in samples
from zoledronic acid treated animals compared to control. A
direct link between osteoclast size and anti-resorptive activity
could not be established in the present study, as serum CTX levels
did not reﬂect the treatment-induced changes in bone structure.
This was most likely due to the 2–3 week time gap between
treatment and the collection of serum.
Similar to the results observed in the tumour-free bones, albeit
less extensive, was that the main bone cell affected by zoledronic
acid in tumour-bearing bone was the osteoblast, with major
reductions in cell number and activity (PINP) detectable on day
15. Zoledronic acid treatment may therefore effectively counter-
act the tumour-induced changes in both osteoblast and osteoclast
numbers evident in bones from control animals treated with PBS.
The effects on the bone microenvironment were caused by
zoledronic acid, as doxorubicin treatment had no effect on bone
cell numbers and there was no synergistic effect following
combination treatment.
In summary, we have shown that administration of a single
round of combination therapy signiﬁcantly reduces tumour bur-
den and preserves bone integrity, but is not sufﬁcient to eliminate
tumour growth in bone. Our results are in agreement with the
established clinical effects of zoledronic acid in the advanced
cancer setting, showing a dampening of disease rather than
elimination of bone metastasis [35]. Our data show that althoughzoledronic acid modiﬁes the bone microenvironment through
effects on both osteoblasts and osteoclasts, this does not result
in a signiﬁcant anti-tumour effect in the absence of doxorubicin.
As indicated by the recently published data from the AZURE trial
[7], additional components of the bone microenvironment linked
to menopausal status may be the key to the development of
tumour growth in bone and response to combination therapy.Acknowledgements
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